CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

CAMP4 Therapeutics (Nasdaq: CAMP) announced on December 11, 2025 that its Board approved inducement grants under Nasdaq Listing Rule 5635(c)(4).

The Board granted non-qualified stock options to purchase an aggregate of 92,000 shares to four newly hired employees. Each option has a ten-year term and an exercise price of $6.01, equal to CAMP4’s closing share price on the grant date.

The options vest over four years with 25% vesting at the one-year anniversary and the remainder vesting in 36 equal monthly installments, subject to continued service and the terms of an Inducement Option Award Agreement.

News Market Reaction

+4.01% 2.1x vol

6 alerts

+4.01% News Effect

+17.2% Peak in 6 hr 21 min

+$12M Valuation Impact

$310M Market Cap

2.1x Rel. Volume

On the day this news was published, CAMP gained 4.01%, reflecting a moderate positive market reaction. Argus tracked a peak move of +17.2% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $12M to the company's valuation, bringing the market cap to $310M at that time. Trading volume was elevated at 2.1x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement options: 92,000 shares Number of employees: 4 employees Option term: 10 years +3 more

6 metrics

Inducement options 92,000 shares Aggregate non-qualified stock options granted to four new employees

Number of employees 4 employees Recipients of inducement stock option grants

Option term 10 years Term of the inducement stock options

Exercise price $6.01 per share Equal to CAMP’s closing price on the Dec 11, 2025 grant date

Initial vesting 25% after 1 year Portion of each grant vesting on first anniversary of employment

Remaining vesting 36 monthly installments Remainder of options vest monthly thereafter, subject to service

Market Reality Check

Price: $4.00 Vol: Volume 215,979 vs 20-day ...

high vol

$4.00 Last Close

Volume Volume 215,979 vs 20-day average 107,277, showing relative volume of 2.01x before this filing. high

Technical Shares traded above the 200-day MA, at $6.01 vs 200-day MA of $2.72 ahead of the news.

Peers on Argus

Peers in Biotechnology showed mixed moves, with names like CUE at -0.94%, DTIL a...

Peers in Biotechnology showed mixed moves, with names like CUE at -0.94%, DTIL at -2.19%, PDSB at +1.0%, PYPD at -1.49%, and ADVM at +2.83%, suggesting CAMP’s pre-news strength was stock-specific rather than a broad sector move.

Historical Context

5 past events · Latest: Nov 14 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 14	Inducement stock grant	Neutral	-2.7%	Single inducement option for 80,000 shares with standard four-year vesting.
Nov 6	Q3 2025 earnings	Positive	+7.0%	Runway-extend­ing private placement, higher cash and continued pipeline progress.
Oct 1	GLP tox initiation	Positive	-1.7%	Started GLP toxicology for SYNGAP1 candidate aiming for Phase 1/2 in H2 2026.
Sep 10	Private placement	Positive	+40.2%	Oversubscribed up to $100M financing to advance SYNGAP1 program and leadership changes.
Aug 14	Q2 2025 earnings	Positive	+7.7%	Positive translational data, GLP tox plans, and detailed cash and expense profile.

Pattern Detected

Recent history shows positive reactions to financings and earnings, while operational updates and inducement grants have seen more muted or mixed price responses.

Recent Company History

Over the last few months, CAMP4 reported Q2 and Q3 2025 results with pipeline progress and cash balances up to $75.3M, alongside an oversubscribed private placement of up to $100M that drove a 40.2% move. The company also advanced SYNGAP1 programs into GLP tox and issued prior inducement option grants. Today’s additional inducement awards fit an ongoing pattern of using equity-based compensation alongside larger capital-raising and development milestones.

Regulatory & Risk Context

Active S-3 Shelf · $300,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-10

$300,000,000 registered capacity

An effective Form S-3 shelf filed on Nov 10, 2025 registers up to $300,000,000 of securities and includes an ATM program of up to $100,000,000 via Leerink Partners, giving CAMP4 substantial capacity to issue equity or other securities over time.

Market Pulse Summary

This announcement details inducement grants of 92,000 non-qualified stock options to four new employ...

Analysis

This announcement details inducement grants of 92,000 non-qualified stock options to four new employees at an exercise price of $6.01, matching the grant-date close. The options vest over four years, reinforcing long-term alignment through equity compensation. In the broader context of recent private placement financing and a shelf registration for up to $300,000,000 plus a $100,000,000 ATM, investors may monitor how additional equity issuance and pipeline milestones interact with overall dilution and execution risk.

Key Terms

non-qualified stock options, Nasdaq Listing Rule 5635(c)(4), exercise price

3 terms

non-qualified stock options financial

"the Company’s Board of Directors granted non-qualified stock options"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

Nasdaq Listing Rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"an exercise price per share of $6.01, which is equal to the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on December 11, 2025 (the “Grant Date”), the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 92,000 shares of the Company’s common stock to four newly hired employees of the Company, each as an inducement material to each employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”).

The Inducement Grants each have a ten-year term and an exercise price per share of $6.01, which is equal to the closing price of CAMP4’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments, subject to the employee’s continued service with CAMP4 through the applicable vesting dates. Each Inducement Grant was granted pursuant to, and is subject to, the terms and conditions of an Inducement Option Award Agreement.

About CAMP4 Therapeutics 
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com. 

Contacts

Investor Relations:
Sara Michelmore
Milestone Advisors
sara@milestone-advisorsllc.com

Media:
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com

FAQ

What did CAMP4 (CAMP) announce on December 11, 2025?

CAMP4 granted non-qualified stock options to four new hires totaling 92,000 shares as inducement awards under Nasdaq Rule 5635(c)(4).

What is the exercise price and term of the CAMP4 inducement options (CAMP)?

Each option has a 10-year term and an exercise price of $6.01, equal to the closing price on the grant date.

How do the CAMP4 inducement grants vest for new employees?

The grants vest over four years: 25% at the one-year anniversary, then the remainder in 36 equal monthly installments, subject to continued service.

How many employees received inducement option grants from CAMP4 (CAMP)?

The Board granted inducement options to four newly hired employees.

Do CAMP4 inducement grants follow Nasdaq Listing Rule 5635(c)(4)?

Yes; the company granted the options as inducement awards in accordance with Nasdaq Listing Rule 5635(c)(4).